ALKS Biotechnology · Neuroscience · Sleep disorders · Thesis updated August 5, 2026

Sleep pivot pays off as generic cliff fades

Alkermes removed a major near-term fear by confirming VIVITROL will not face an authorized generic in 2027.
The new sleep drug LUMRYZ reached 3,900 patients and generated $96.6 million in the second quarter of 2026.
Second-quarter proprietary product sales hit $411.7 million, showing the strength of the commercial portfolio.
LYBALVI secured expanded Medicare Part D access, which drives volume but increases price deductions.
The company carries heavy debt from the Avadel deal and is funding expensive trials for new orexin medicines.

01 Running thesis

A clearer path for the legacy portfolio

Alkermes is changing shape. It historically leaned on older brain medicines like LYBALVI, VIVITROL, and ARISTADA. After buying Avadel in early 2026, it added LUMRYZ, a once-at-bedtime oxybate for narcolepsy. This gave the company a real sleep medicine business before its experimental drug alixorexton reaches the market.

The bull case improved significantly in mid-2026. Management confirmed that VIVITROL will not face an authorized generic in 2027. This removes a major near-term threat to the cash flow that funds the pipeline. At the same time, LUMRYZ adoption accelerated to 3,900 patients, proving the Avadel acquisition is working.

The pipeline story is also getting wider. Alkermes is testing ALKS 7290 in adult ADHD and preparing ALKS 4510 for fatigue linked to multiple sclerosis and Parkinson's disease. The drug platform is growing, but the proof still has to come from larger clinical trials.

The bear case centers on costs and debt. Alkermes took on roughly $1.525 billion of debt for Avadel. The company must manage these interest payments while funding expensive Phase 3 alixorexton studies and new mid-stage trials. Meanwhile, LYBALVI will face higher price deductions as it enters more Medicare Part D plans.

Jul 2026▲Management confirmed VIVITROL will not face an authorized generic in 2027, removing a near-term revenue cliff. LUMRYZ adoption also accelerated, reaching 3,900 patients.

May 2026▲Alkermes broadened the orexin story by starting ALKS 7290 work in adult ADHD and preparing ALKS 4510 for fatigue in multiple sclerosis and Parkinson's disease.

May 2026▼Q1 2026 made the pressure points clearer. The company is carrying Avadel acquisition debt and management discussed possible Teva generic VIVITROL entry in early 2027.

Feb 2026▲The Avadel acquisition closed on February 12, 2026, adding LUMRYZ and a narcolepsy commercial team. The deal made Alkermes a real sleep medicine seller.

Oct 2025▲Alkermes announced the Avadel deal plan and showed continued LYBALVI growth. The sleep strategy became more concrete, but integration and financing risk also entered the story.

Jul 2025▲Alixorexton met the primary endpoint in a Phase 2 narcolepsy type 1 study, and Alkermes moved toward Phase 3 planning. That reduced some pipeline risk around the lead orexin drug.

May 2025→Q1 2025 showed the older royalty decline was real, while LYBALVI growth helped offset it. The company became more dependent on proprietary product execution.

02 Business model

Selling today, funding trials for tomorrow

Alkermes makes money mostly by selling its own medicines. In the second quarter of 2026, proprietary product sales were $411.7 million. VIVITROL contributed $124.5 million, ARISTADA family products added $96.7 million, LUMRYZ brought in $96.6 million, and LYBALVI generated $94.0 million.

The smaller revenue stream is manufacturing and royalty revenue. This line was $84.3 million in the second quarter of 2026. This segment continues a planned decline as older patents expire.

The model works if marketed products produce enough cash to pay debt service and fund trials. LUMRYZ growth and the delay of generic VIVITROL help immensely. If LUMRYZ adoption stalls or trial costs spiral out of control, the company will have less financial flexibility.

03 Product portfolio

The drugs that carry the story

Growth engine

LYBALVI

LYBALVI treats schizophrenia and bipolar I disorder. It produced Q2 2026 sales of $94.0 million and recently gained broad Medicare Part D access.

Cash cow

VIVITROL

VIVITROL is used for alcohol and opioid dependence. It had Q2 2026 sales of $124.5 million. Management does not expect an authorized generic to enter the market in 2027.

Steady

ARISTADA product family

ARISTADA and ARISTADA INITIO are long-acting schizophrenia medicines. The family had Q2 2026 sales of $96.7 million and provides steady cash flow.

Growth engine

LUMRYZ

LUMRYZ is a once-at-bedtime oxybate for narcolepsy. It added $96.6 million of sales in Q2 2026 and had roughly 3,900 patients on therapy exiting the quarter.

Option

Alixorexton

Alixorexton is an orexin 2 receptor agonist in Phase 3 for narcolepsy type 1 and type 2. The Brilliance Studies are the central late-stage pipeline program.

Option

ALKS 7290 and ALKS 4510

ALKS 7290 is in early trials for adult ADHD. ALKS 4510 is planned for studies in fatigue linked to multiple sclerosis and Parkinson's disease.

04 Business segments

Product sales dominate the mix

Proprietary product sales83%growing fast

Manufacturing and royalty revenues17%declining

The mix uses Q2 2026 revenue. Proprietary product sales were $411.7 million, while manufacturing and royalty revenues were $84.3 million.

05 Risk factors

What could break the thesis

Avadel debt load

High impact · Medium odds

Alkermes incurred about $1.525 billion of debt to finance the Avadel acquisition. That debt requires high interest payments and limits flexibility if product growth slows.

We watchQuarterly interest expense, cash balance, and management's updated debt repayment plan.

LYBALVI gross-to-net pressure

Medium impact · High odds

LYBALVI secured expanded Medicare Part D formulary access. This covers more patients but increases gross-to-net deductions, which could limit revenue growth even as volumes rise.

We watchNet revenue growth for LYBALVI and management comments on gross-to-net percentages.

Orexin trials may not translate

High impact · Medium odds

Alixorexton is in Phase 3, and Alkermes is pushing other orexin drugs into ADHD and fatigue. These areas are competitive, and early promise does not always become strong Phase 3 data.

We watchBrilliance Studies enrollment, Vibrance-3 top-line data expected in Q4 2026, and ALKS 7290 adult ADHD data.

Generic competition timing

High impact · Low odds

While management confirmed no authorized generic for VIVITROL in 2027, the exact timing of generic entry remains uncertain for the years following. A sudden launch would hit cash flows hard.

We watchAny legal or FDA updates tied to Teva's generic VIVITROL path for 2028 or beyond.

06 Quick answers

In one breath

What does Alkermes do?

Alkermes develops and sells medicines for brain and nervous system disorders. Its marketed products include LYBALVI, VIVITROL, ARISTADA, and LUMRYZ.

Why did Alkermes buy Avadel?

Avadel gave Alkermes LUMRYZ, an approved narcolepsy drug, plus a sleep medicine sales team. That helps Alkermes build a market presence before a possible future alixorexton launch.

What is the most important pipeline drug?

Alixorexton is the lead pipeline drug. It is an orexin 2 receptor agonist in Phase 3 studies for narcolepsy type 1 and type 2.